出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年10月
Gene Therapy Market – Global Forecast to 2028
遺伝子治療市場 : タイプ（遺伝子サイレンシング、遺伝子増強）、ベクター［ウイルス（レトロウイルス、AAV）、非ウイルス（オリゴヌクレオチド）］、治療領域（神経学、腫瘍学）、送達方法（生体内、体外）、RoA（静脈内）、地域別 – 2028年までの世界予測
Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region – Global Forecast to 2028
| ページ数 | 276 |
| 図表数 | 397 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The gene therapy market is expected to reach USD 23.9 billion by 2028 from USD 9.0 billion in 2023, at a CAGR of 21.4% during the forecast period. The key factors driving the growth of the gene therapy market include increasing initiatives related to genomic research, and increasing number of regulatory approvals for gene therapy products. Moreover, growing demand for cell and gene therapies is an opportunity area for this market.
The gene therapy market has been segmented based on type, vector, therapeutic area, delivery method, route of administration and region.
“By therapeutic area, oncology segment accounted for the second largest share of the gene therapy market”
Based on type, the gene therapy market is categorized into neurology, oncology, hepatology, and other therapeutic areas.. In 2022, oncology accounted for the highest growth rate owing to factors such as The rising demand for targeted therapies (including gene therapy) against cancer, increasing cancer prevalence are the major factors driving the growth of this segment.
“By delivery method, the in vivo segment accounted for the largest share in the gene therapy market”
Based on end user, the gene therapy market is segmented into the gene therapy market is segmented into in vivo and ex vivo. In 2022, the in vivo segment accounted for a largest share of the gene therapy market. Growth in this market segment can be attributed to availability of many in vivo gene therapy products commercially and focus of research and development on this delivery method.
“North America: the largest share of the gene therapy market”
North America accounted for the largest share of the gene therapy market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering gene therapies, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, presence of some of the key players in the market is another key factor. Some examples of these players include Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others.
“Europe: The fastest-growing region in the gene therapy market.”
The Europe gene therapy market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of gene therapies, increasing prevalence of chronic diseases and support offered by the government organizations for developing advanced targeted therapies.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, Directors- 30%, and Executives – 25%
• By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%
Prominent Players
• Novartis AG (Switzerland)
• Biogen Inc. (US)
• Gilead Sciences, Inc. (US)
• Bristol-Myers Squibb (US)
• Alnylam Pharmaceuticals, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Amgen, Inc. (US)
• Orchard Therapeutics Plc (UK)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Jazz Pharmaceuticals Plc (Ireland)
• uniQure N.V. (Netherlands)
• Johnson & Johnson (US)
• Bluebird Bio, Inc. (US)
• BioMarin Pharmaceutical Inc. (US)
• Krystal Biotech, Inc. (US)
• Shanghai Sunway Biotech Co. Ltd. (China)
• SIBIONO GeneTech Co. Ltd. (China)
• Ferring B.V. (Switzerland)
• Vertex Pharmaceuticals Incorporated (US)
• Pfizer, Inc. (US)
• Sangamo Therapeutics, Inc. (US)
• REGENXBIO (US)
• Ultragenyx Pharmaceutical Inc. (US)
• MeiraGTx Holdings Plc (US)
• AnGes, Inc. (Japan)
Research Coverage:
This report provides a detailed picture of the gene therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers
• Analysis of key drivers (growth in regulatory approvals for gene therapy products), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with supply chain) influencing the growth of the gene therapy market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the gene therapy market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the gene therapy market across varied regions.
• Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the gene therapy market.
• Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Amgen, Inc. (US), Orchard Therapeutics Plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), among others in the gene therapy market.
Table of Contents
1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS & EXCLUSIONS 41
1.3 MARKET SCOPE 41
1.3.1 MARKETS COVERED 41
FIGURE 1 GENE THERAPY MARKET SEGMENTATION 41
1.3.2 YEARS CONSIDERED 42
1.4 CURRENCY CONSIDERED 42
1.5 LIMITATIONS 42
1.6 STAKEHOLDERS 43
1.7 SUMMARY OF CHANGES 43
1.7.1 RECESSION IMPACT 43
2 RESEARCH METHODOLOGY 44
2.1 RESEARCH DATA 44
FIGURE 2 RESEARCH DESIGN 44
2.1.1 SECONDARY DATA 45
2.1.2 PRIMARY DATA 46
FIGURE 3 GENE THERAPY MARKET: BREAKDOWN OF PRIMARIES 46
2.2 MARKET SIZE ESTIMATION OF GENE THERAPY MARKET 47
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 47
FIGURE 5 MARKET SIZE ESTIMATION FOR GENE THERAPY MARKET: REVENUE SHARE ANALYSIS 48
2.2.1 INSIGHTS FROM PRIMARIES 49
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 49
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 50
2.3 GROWTH FORECAST 51
FIGURE 8 GENE THERAPY MARKET: CAGR PROJECTIONS 51
FIGURE 9 GENE THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 53
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
2.5 RESEARCH ASSUMPTIONS 54
2.6 RISK ANALYSIS 54
2.7 RECESSION IMPACT ANALYSIS 54
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 54
3 EXECUTIVE SUMMARY 56
FIGURE 11 GENE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 56
FIGURE 12 GENE THERAPY MARKET, BY VECTOR, 2023 VS. 2028 (USD MILLION) 57
FIGURE 13 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 57
FIGURE 14 GENE THERAPY MARKET, BY DELIVERY METHOD, 2023 VS. 2028 (USD MILLION) 58
FIGURE 15 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION) 58
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET 59
4 PREMIUM INSIGHTS 60
4.1 GENE THERAPY MARKET OVERVIEW 60
FIGURE 17 INCREASING INVESTMENTS IN GENE THERAPY RESEARCH TO DRIVE GROWTH IN GENE THERAPY MARKET 60
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA & COUNTRY (2022) 61
FIGURE 18 NEUROLOGY ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 61
4.3 GENE THERAPY MARKET, BY VECTOR, 2022 62
FIGURE 19 VIRAL VECTORS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 62
4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62
FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
FIGURE 21 GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
5.2.1 DRIVERS 64
5.2.1.1 Increasing regulatory approvals for gene therapy products 64
TABLE 2 LIST OF KEY PRODUCT APPROVALS IN GENE THERAPY MARKET, 2021–2023 64
5.2.1.2 Increasing investments in gene therapy research 65
5.2.1.3 Growing technological advancements 66
TABLE 3 LIST OF ADVANCED PLATFORMS LAUNCHED IN GENE THERAPY MARKET, 2022–2023 66
5.2.1.4 Rising prevalence of genetic disorders and cancer 67
5.2.2 RESTRAINTS 67
5.2.2.1 High cost of gene therapy products 67
TABLE 4 COST OF GENE THERAPY PRODUCTS 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Rising demand for cell & gene therapies 69
5.2.3.2 Increasing focus on precision medicine 69
5.2.4 CHALLENGES 70
5.2.4.1 Complex manufacturing process 70
5.2.4.2 Short shelf life and supply chain challenges 70
5.3 PORTER’S FIVE FORCES ANALYSIS 71
TABLE 5 GENE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 71
5.3.1 THREAT OF NEW ENTRANTS 71
5.3.2 THREAT OF SUBSTITUTES 71
5.3.3 BARGAINING POWER OF SUPPLIERS 71
5.3.4 BARGAINING POWER OF BUYERS 72
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 72
5.4 TECHNOLOGY ANALYSIS 72
5.5 VALUE CHAIN ANALYSIS 73
FIGURE 22 GENE THERAPY MARKET: VALUE CHAIN 73
5.6 ECOSYSTEM ANALYSIS 74
FIGURE 23 GENE THERAPY MARKET: ECOSYSTEM MAP 74
5.7 PATENT ANALYSIS 75
FIGURE 24 PATENT APPLICATIONS FOR GENE THERAPY PRODUCTS, JANUARY 2012–SEPTEMBER 2023 75
TABLE 6 GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS 76
5.8 PIPELINE ANALYSIS 76
TABLE 7 GENE THERAPY PRODUCTS IN CLINICAL PIPELINE 76
5.9 SUPPLY CHAIN ANALYSIS 78
FIGURE 25 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS 79
TABLE 8 SUPPLY CHAIN ECOSYSTEM 80
5.10 REGULATORY LANDSCAPE 81
5.10.1 REGULATORY ANALYSIS 81
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION 81
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
5.11 PRICING ANALYSIS 83
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS 83
TABLE 13 AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS 83
TABLE 14 AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD 84
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 84
5.13 KEY CONFERENCES & EVENTS 85
TABLE 15 GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024) 85
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 86
5.14.1 KEY STAKEHOLDERS ON BUYING PROCESS 86
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GENE THERAPY PRODUCTS IN HOSPITALS AND CLINICS 86
5.14.2 BUYING CRITERIA FOR GENE THERAPY MARKET 86
FIGURE 27 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS 86
6 GENE THERAPY MARKET, BY TYPE 87
6.1 INTRODUCTION 88
TABLE 16 GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 88
6.2 GENE SILENCING 88
6.2.1 HIGH FLEXIBILITY AND PRECISION OFFERED BY GENE SILENCING THERAPIES TO SUPPORT GROWTH 88
TABLE 17 GENE SILENCING THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 18 NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 19 EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 20 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 21 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
6.3 CELL REPLACEMENT 90
6.3.1 LONG-TERM EFFECTS OF CELL REPLACEMENT THERAPY TO BOOST ADOPTION 90
TABLE 22 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 23 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 24 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 25 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 26 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
6.4 GENE AUGMENTATION 93
6.4.1 GROWING USE OF GENE AUGMENTATION THERAPY AGAINST MONOGENIC DISORDERS TO FAVOR MARKET GROWTH 93
TABLE 27 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 28 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 29 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 30 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 31 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
6.5 OTHER THERAPIES 95
7 GENE THERAPY MARKET, BY VECTOR 96
7.1 INTRODUCTION 97
TABLE 32 GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 97
7.2 VIRAL VECTORS 97
TABLE 33 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 98
TABLE 34 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 35 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 36 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 37 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 38 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 99
7.2.1 RETROVIRAL VECTORS 100
TABLE 39 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 100
TABLE 40 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 41 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 42 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 43 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 44 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 102
7.2.1.1 Gamma retroviral vectors 102
7.2.1.1.1 Availability of wide range of gamma-retroviral vectors to support market growth 102
TABLE 45 GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 46 NORTH AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 47 EUROPE: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 48 ASIA PACIFIC: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 49 LATIN AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 104
7.2.1.2 Lentiviral vectors 104
7.2.1.2.1 North America to dominate lentiviral vectors market 104
TABLE 50 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION) 105
TABLE 51 NORTH AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 52 EUROPE: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 53 ASIA PACIFIC: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 54 LATIN AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 106
7.2.2 ADENO-ASSOCIATED VIRAL VECTORS 107
7.2.2.1 Growing clinical pipeline of adeno-associated viral vectors to drive growth 107
TABLE 55 GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 56 NORTH AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 57 EUROPE: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 58 ASIA PACIFIC: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 59 LATIN AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 109
7.2.3 OTHER VIRAL VECTORS 109
TABLE 60 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 61 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 62 EUROPE: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 63 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 64 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 111
7.3 NON-VIRAL VECTORS 111
TABLE 65 GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 66 GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 67 NORTH AMERICA: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 68 EUROPE: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 69 ASIA PACIFIC: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 70 LATIN AMERICA: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 113
7.3.1 OLIGONUCLEOTIDES 114
7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market 114
TABLE 71 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 72 NORTH AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 73 EUROPE: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 74 ASIA PACIFIC: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 75 LATIN AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION) 115
7.3.2 OTHER NON-VIRAL VECTORS 116
TABLE 76 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 77 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 78 EUROPE: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 79 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 80 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION) 117
8 GENE THERAPY MARKET, BY THERAPEUTIC AREA 118
8.1 INTRODUCTION 119
TABLE 81 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 119
8.2 NEUROLOGY 119
8.2.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH 119
TABLE 82 GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 83 NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 84 EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 85 ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 86 LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 121
8.3 ONCOLOGY 122
8.3.1 GROWING DEMAND FOR TARGETED THERAPIES AGAINST CANCERS TO DRIVE MARKET GROWTH 122
TABLE 87 PIPELINE PRODUCTS FOR ONCOLOGY APPLICATIONS 122
TABLE 88 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 123
TABLE 89 GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 90 NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 91 EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 92 ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 93 LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 125
8.4 HEPATOLOGY 126
8.4.1 GROWING R&D ACTIVITIES FOR LIVER CONDITIONS TO SUPPORT GROWTH 126
TABLE 94 GENE THERAPY MARKET FOR HEPATOLOGY, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 95 NORTH AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 96 EUROPE: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 97 ASIA PACIFIC: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 98 LATIN AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
8.5 OTHER THERAPEUTIC AREAS 128
TABLE 99 GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 100 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 101 EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 102 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 103 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 129
9 GENE THERAPY MARKET, BY DELIVERY METHOD 130
9.1 INTRODUCTION 131
TABLE 104 GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 131
9.2 IN VIVO 131
9.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 131
TABLE 105 COMMERCIALIZED AND PIPELINE IN VIVO-BASED GENE THERAPY PRODUCTS 132
TABLE 106 IN VIVO GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 107 NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 108 EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 109 ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 110 LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
9.3 EX VIVO 134
9.3.1 GROWING FOCUS ON ONCOLOGY BY MARKET PLAYERS TO SUPPORT MARKET GROWTH 134
TABLE 111 COMMERCIALIZED AND PIPELINE EX VIVO-BASED GENE THERAPY PRODUCTS 135
TABLE 112 EX VIVO GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 113 NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 114 EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 115 ASIA PACIFIC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 116 LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
10 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION 138
10.1 INTRODUCTION 139
TABLE 117 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 139
10.2 INTRAVENOUS 139
10.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH 139
TABLE 118 GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 119 NORTH AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 120 EUROPE: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 121 ASIA PACIFIC: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 122 LATIN AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 141
10.3 OTHER ROUTES OF ADMINISTRATION 142
TABLE 123 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 143
TABLE 124 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 125 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 126 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 127 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 144
11 GENE THERAPY MARKET, BY REGION 145
11.1 INTRODUCTION 146
TABLE 128 GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 146
11.2 NORTH AMERICA 147
FIGURE 28 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT 147
TABLE 129 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 130 NORTH AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 131 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 148
TABLE 132 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 133 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 134 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 135 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 150
TABLE 136 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 150
TABLE 137 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 150
11.2.1 US 151
11.2.1.1 Growing regulatory approvals and availability of advanced treatments to drive market growth 151
TABLE 138 US FDA APPROVALS FOR GENE THERAPY PRODUCTS 151
TABLE 139 US: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 140 US: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 152
TABLE 141 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 142 US: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 143 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 144 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 153
TABLE 145 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 153
TABLE 146 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 154
11.2.2 CANADA 154
11.2.2.1 Growing gene therapy research initiatives to support growth 154
TABLE 147 CANADA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 148 CANADA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 155
TABLE 149 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 150 CANADA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 151 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 152 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 156
TABLE 153 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 156
TABLE 154 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 157
11.2.3 NORTH AMERICA: RECESSION IMPACT 157
11.3 EUROPE 158
FIGURE 29 EUROPE: GENE THERAPY MARKET SNAPSHOT 159
TABLE 155 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 156 EUROPE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 157 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 160
TABLE 158 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 159 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 160 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 161 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 162
TABLE 162 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 162
TABLE 163 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 162
11.3.1 GERMANY 163
11.3.1.1 Growing collaborations in market to boost growth 163
TABLE 164 GERMANY: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 165 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 164
TABLE 166 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 167 GERMANY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 168 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 169 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 165
TABLE 170 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 165
TABLE 171 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 166
11.3.2 UK 166
11.3.2.1 Strong government support to drive market growth 166
TABLE 172 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 166
TABLE 173 UK: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 174 UK: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 167
TABLE 175 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 176 UK: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 177 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 178 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 168
TABLE 179 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 169
TABLE 180 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 169
11.3.3 FRANCE 169
11.3.3.1 Increasing initiatives in genomic research to drive market 169
TABLE 181 FRANCE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 182 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 170
TABLE 183 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 184 FRANCE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 185 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 186 FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 171
TABLE 187 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 172
TABLE 188 FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 172
11.3.4 ITALY 172
11.3.4.1 Initiatives for gene therapy development to drive growth 172
TABLE 189 ITALY: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 190 ITALY: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 173
TABLE 191 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 192 ITALY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 193 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 194 ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 174
TABLE 195 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 175
TABLE 196 ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 175
11.3.5 SPAIN 175
11.3.5.1 Genomics initiatives and funding to support market growth 175
TABLE 197 SPAIN: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 198 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 176
TABLE 199 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 200 SPAIN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 201 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 202 SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 177
TABLE 203 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 178
TABLE 204 SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 178
11.3.6 REST OF EUROPE 178
TABLE 205 REST OF EUROPE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 206 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 179
TABLE 207 REST OF EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 208 REST OF EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 209 REST OF EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 210 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 180
TABLE 211 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 181
TABLE 212 REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 181
11.3.7 EUROPE: RECESSION IMPACT 181
11.4 ASIA PACIFIC 182
TABLE 213 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 214 ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 215 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 183
TABLE 216 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 217 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 218 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 219 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 184
TABLE 220 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 184
TABLE 221 ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 185
11.4.1 CHINA 185
11.4.1.1 China to dominate gene therapy market in APAC during forecast period 185
TABLE 222 CHINA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 223 CHINA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 186
TABLE 224 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 225 CHINA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 226 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 227 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 187
TABLE 228 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 187
TABLE 229 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 188
11.4.2 JAPAN 188
11.4.2.1 Increasing initiatives supporting gene therapy adoption to propel market growth 188
TABLE 230 JAPAN: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 231 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 189
TABLE 232 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 233 JAPAN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 234 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 235 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 190
TABLE 236 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 191
TABLE 237 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 191
11.4.3 INDIA 191
11.4.3.1 Increasing burden of chronic diseases to drive market growth 191
TABLE 238 INDIA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 239 INDIA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 192
TABLE 240 INDIA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 241 INDIA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 242 INDIA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 243 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 193
TABLE 244 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 194
TABLE 245 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 194
11.4.4 REST OF ASIA PACIFIC 194
TABLE 246 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 247 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 195
TABLE 248 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 249 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 250 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 251 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 196
TABLE 252 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 197
TABLE 253 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 197
11.4.5 ASIA PACIFIC: RECESSION IMPACT 197
11.5 LATIN AMERICA 198
TABLE 254 LATIN AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 198
TABLE 255 LATIN AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 256 LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 199
TABLE 257 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 258 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 259 LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 260 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 200
TABLE 261 LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 200
TABLE 262 LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 201
11.5.1 BRAZIL 201
11.5.1.1 Gradual increase in pharmaceutical R&D to support market growth 201
TABLE 263 BRAZIL: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 264 BRAZIL: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 202
TABLE 265 BRAZIL: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 266 BRAZIL: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 267 BRAZIL: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 268 BRAZIL: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 203
TABLE 269 BRAZIL: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 203
TABLE 270 BRAZIL: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 204
11.5.2 REST OF LATIN AMERICA 204
TABLE 271 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 272 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 205
TABLE 273 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 274 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 275 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 276 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 206
TABLE 277 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 206
TABLE 278 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 207
11.5.3 LATIN AMERICA: RECESSION IMPACT 207
11.6 MIDDLE EAST 207
11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS 207
TABLE 279 MIDDLE EAST: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 280 MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 208
TABLE 281 MIDDLE EAST: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 282 MIDDLE EAST: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 283 MIDDLE EAST: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 284 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209
TABLE 285 MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 210
TABLE 286 MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 210
11.6.2 MIDDLE EAST: RECESSION IMPACT 210
11.7 AFRICA 211
11.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS 211
TABLE 287 AFRICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 288 AFRICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION) 211
TABLE 289 AFRICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 290 AFRICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 291 AFRICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 292 AFRICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 213
TABLE 293 AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION) 213
TABLE 294 AFRICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 213
11.7.2 AFRICA: RECESSION IMPACT 214
12 COMPETITIVE LANDSCAPE 215
12.1 KEY PLAYER STRATEGIES 215
FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET 215
12.2 MARKET SHARE ANALYSIS 216
FIGURE 31 GENE THERAPY MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 216
TABLE 295 GENE THERAPY MARKET: DEGREE OF COMPETITION 216
12.3 REVENUE ANALYSIS 217
FIGURE 32 REVENUE ANALYSIS FOR KEY COMPANIES (2020–2022) 217
12.4 COMPANY EVALUATION MATRIX 218
12.4.1 STARS 218
12.4.2 EMERGING LEADERS 218
12.4.3 PERVASIVE PLAYERS 218
12.4.4 PARTICIPANTS 218
FIGURE 33 COMPANY EVALUATION MATRIX, 2022 219
12.4.5 COMPANY FOOTPRINT 220
12.4.5.1 Company therapeutic area footprint 220
TABLE 296 THERAPEUTIC AREA FOOTPRINT ANALYSIS OF KEY PLAYERS IN GENE THERAPY MARKET 220
12.4.5.2 Company regional footprint 221
TABLE 297 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN GENE THERAPY MARKET 221
12.5 START-UP/SME EVALUATION MATRIX 222
12.5.1 PROGRESSIVE COMPANIES 222
12.5.2 RESPONSIVE COMPANIES 222
12.5.3 DYNAMIC COMPANIES 223
12.5.4 STARTING BLOCKS 223
FIGURE 34 START-UP/SME EVALUATION MATRIX, 2022 223
12.5.5 COMPETITIVE BENCHMARKING 224
TABLE 298 GENE THERAPY MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 224
TABLE 299 GENE THERAPY MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 224
12.6 COMPETITIVE SCENARIO AND TRENDS 225
12.6.1 PRODUCT APPROVALS 225
TABLE 300 GENE THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2020–AUGUST 2023 225
12.6.2 DEALS 226
TABLE 301 GENE THERAPY MARKET: DEALS, JANUARY 2020–AUGUST 2023 226
12.6.3 OTHER DEVELOPMENTS 226
TABLE 302 GENE THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2023 226
13 COMPANY PROFILES 227
13.1 KEY PLAYERS 227
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 NOVARTIS AG 227
TABLE 303 NOVARTIS AG: COMPANY OVERVIEW 227
FIGURE 35 NOVARTIS AG: COMPANY SNAPSHOT (2022) 228
TABLE 304 NOVARTIS AG: PRODUCT APPROVALS 229
TABLE 305 NOVARTIS AG: DEALS 229
TABLE 306 NOVARTIS AG: OTHER DEVELOPMENTS 230
13.1.2 BIOGEN INC. 232
TABLE 307 BIOGEN INC.: COMPANY OVERVIEW 232
FIGURE 36 BIOGEN INC.: COMPANY SNAPSHOT (2022) 233
TABLE 308 BIOGEN INC.: DEALS 234
TABLE 309 BIOGEN INC.: OTHER DEVELOPMENTS 235
13.1.3 GILEAD SCIENCES, INC. 236
TABLE 310 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 236
FIGURE 37 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022) 237
TABLE 311 GILEAD SCIENCES, INC.: PRODUCT APPROVALS 238
TABLE 312 GILEAD SCIENCES, INC.: DEALS 238
TABLE 313 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS 239
13.1.4 BRISTOL-MYERS SQUIBB 240
TABLE 314 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW 240
FIGURE 38 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2022) 241
TABLE 315 BRISTOL-MYERS SQUIBB: PRODUCT APPROVALS 242
TABLE 316 BRISTOL-MYERS SQUIBB: DEALS 242
13.1.5 ALNYLAM PHARMACEUTICALS, INC. 243
TABLE 317 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 243
FIGURE 39 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022) 244
TABLE 318 ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS 245
TABLE 319 ALNYLAM PHARMACEUTICALS, INC.: DEALS 245
13.1.6 SAREPTA THERAPEUTICS, INC. 246
TABLE 320 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 246
FIGURE 40 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022) 246
TABLE 321 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS 247
TABLE 322 SAREPTA THERAPEUTICS, INC.: DEALS 247
TABLE 323 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS 249
13.1.7 AMGEN, INC. 250
TABLE 324 AMGEN, INC.: COMPANY OVERVIEW 250
FIGURE 41 AMGEN, INC.: COMPANY SNAPSHOT (2022) 251
TABLE 325 AMGEN, INC.: DEALS 252
TABLE 326 AMGEN, INC.: OTHER DEVELOPMENTS 252
13.1.8 ORCHARD THERAPEUTICS PLC 253
TABLE 327 ORCHARD THERAPEUTICS PLC: COMPANY OVERVIEW 253
FIGURE 42 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT (2022) 254
TABLE 328 ORCHARD THERAPEUTICS PLC: PRODUCT APPROVALS 255
TABLE 329 ORCHARD THERAPEUTICS PLC: DEALS 256
13.1.9 F. HOFFMANN-LA ROCHE AG 257
TABLE 330 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 257
FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022) 258
13.1.10 JAZZ PHARMACEUTICALS PLC 259
TABLE 331 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW 259
FIGURE 44 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2022) 260
TABLE 332 JAZZ PHARMACEUTICALS PLC: DEALS 261
13.1.11 UNIQURE N.V. 262
TABLE 333 UNIQURE N.V.: COMPANY OVERVIEW 262
FIGURE 45 UNIQURE N.V.: COMPANY SNAPSHOT (2022) 262
TABLE 334 UNIQURE N.V.: PRODUCT APPROVALS 263
TABLE 335 UNIQURE N.V.: DEALS 263
13.1.12 JOHNSON & JOHNSON 265
TABLE 336 JOHNSON & JOHNSON: COMPANY OVERVIEW 265
FIGURE 46 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022) 266
TABLE 337 JOHNSON & JOHNSON: PRODUCT APPROVALS 267
TABLE 338 JOHNSON & JOHNSON: DEALS 267
13.1.13 BLUEBIRD BIO, INC. 268
TABLE 339 BLUEBIRD BIO, INC.: COMPANY OVERVIEW 268
FIGURE 47 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022) 268
TABLE 340 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES & APPROVALS 269
13.1.14 BIOMARIN PHARMACEUTICAL INC. 270
TABLE 341 BIOMARIN PHARMACEUTICAL INC.: COMPANY OVERVIEW 270
FIGURE 48 BIOMARIN PHARMACEUTICAL INC.: COMPANY SNAPSHOT (2022) 270
TABLE 342 BIOMARIN PHARMACEUTICAL INC.: DEALS 271
TABLE 343 BIOMARIN PHARMACEUTICAL INC.: PRODUCT APPROVALS 271
13.1.15 KRYSTAL BIOTECH, INC. 272
TABLE 344 KRYSTAL BIOTECH, INC.: COMPANY OVERVIEW 272
TABLE 345 KRYSTAL BIOTECH, INC.: PRODUCT APPROVALS 273
TABLE 346 KRYSTAL BIOTECH, INC.: DEALS 273
TABLE 347 KRYSTAL BIOTECH, INC.: OTHER DEVELOPMENTS 273
13.1.16 SHANGHAI SUNWAY BIOTECH CO. LTD. 274
TABLE 348 SHANGHAI SUNWAY BIOTECH CO. LTD.: COMPANY OVERVIEW 274
13.1.17 SIBIONO GENETECH CO. LTD. 275
TABLE 349 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW 275
13.2 OTHER PLAYERS 276
13.2.1 FERRING B.V. 276
13.2.2 VERTEX PHARMACEUTICALS INCORPORATED 277
13.2.3 PFIZER, INC. 277
13.2.4 SANGAMO THERAPEUTICS, INC. 278
13.2.5 REGENXBIO 278
13.2.6 ULTRAGENYX PHARMACEUTICAL INC. 279
13.2.7 MEIRAGTX HOLDINGS PLC 280
13.2.8 ANGES, INC. 280
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 281
14.1 DISCUSSION GUIDE 281
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 285
14.3 CUSTOMIZATION OPTIONS 287
14.4 RELATED REPORTS 287
14.5 AUTHOR DETAILS 288